Amarin to Report First Quarter Results and Host Conference Call on April 29, 2021
April 20 2021 - 6:05AM
Amarin Corporation plc (NASDAQ:AMRN) today announced that it will
host a conference call with members of Amarin senior management to
discuss the company's first quarter 2021 financial results and
provide an operational update on Thursday, April 29, 2021, at 7:30
a.m. ET. The conference call will follow the anticipated release of
the company's financial results earlier that day.
Conference Call and Webcast
Information:
Amarin will host a conference call April 29,
2021, at 7:30 a.m. ET to discuss this information. The conference
call can be heard live on the investor relations section of the
company's website at www.amarincorp.com, or via telephone by
dialing 888-506-0062 within the United States, 973-528-0011 from
outside the United States, and referencing conference ID 942273. A
replay of the call will be made available for a period of two weeks
following the conference call. To hear a replay of the call, dial
877-481-4010, PIN: 40926. A replay of the call will also be
available through the company's website shortly after the call.
To Ask Questions:
During the teleconference, following prepared
remarks, management will respond to questions from investors and
analysts, subject to time limitations. Participants in the live
teleconference will be provided an opportunity to ask questions.
Investors may also e-mail their questions to
investor.relations@amarincorp.com. Email questions will be accepted
until Wednesday, April 28, 2021 at 4:00 p.m. ET.
About Amarin
Amarin is an innovative pharmaceutical company
leading a new paradigm in cardiovascular disease management. From
our scientific research foundation to our focus on clinical trials,
and now our commercial expansion, we are evolving and growing
rapidly. Amarin has offices in Bridgewater, New Jersey in the
United States, Dublin in Ireland, and Zug in Switzerland as well as
commercial partners and suppliers around the world. We are
committed to rethinking cardiovascular risk through the advancement
of scientific understanding of the impact on society of significant
residual risk that exists beyond traditional therapies, such as
statins for cholesterol management.
Availability of Other Information About
Amarin
Investors and others should note that Amarin
communicates with its investors and the public using the company
website (www.amarincorp.com), the investor
relations website (investor.amarincorp.com),
including but not limited to investor presentations and investor
FAQs, Securities and Exchange Commission filings, press releases,
public conference calls and webcasts. The information that Amarin
posts on these channels and websites could be deemed to be material
information. As a result, Amarin encourages investors, the media,
and others interested in Amarin to review the information that is
posted on these channels, including the investor relations website,
on a regular basis. This list of channels may be updated from time
to time on Amarin’s investor relations website and may include
social media channels. The contents of Amarin’s website or these
channels, or any other website that may be accessed from its
website or these channels, shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Investor Inquiries:Investor RelationsAmarin
Corporation plcIn U.S.: +1 (908) 719-1315 IR@amarincorp.com
(investor inquiries)
Solebury Troutamarinir@troutgroup.com
Media Inquiries:CommunicationsAmarin Corporation
plcIn U.S.: +1 (908) 892-2028 PR@amarincorp.com (media
inquiries)
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Sep 2023 to Sep 2024